2. Introduction
Gastrointestinal Tract (GIT)
Continuous tube extending from the
Mouth to the anus
Major function:
Convert complex compounds into simpler
compounds that can be absorbed and used by
cells
Also excretes waste products from the body
2
8/30/2022 Mona. F(Medchem I)
3. Introduction cont.
Characteristic feature of mammalian stomach
It has an ability to secrete acid as part of its involvement in food
digestion
Presence of acid in the stomach or low pH
Stimulates production of proteolytic pepsin enzymes
Acidic pH and proteolytic enzymes
Required for hydrolysis of proteins & other foods
Gastric acid secretion is stimulated by food-related signals that
stimulate
The release of acid from specialized cells within the stomach,
i.e. parietal cells
4
8/30/2022 Mona. F(Medchem I)
4. Gastric Acid (HCl)
Uses:
Kill bacteria found in ingested food & drink
Soften fibrous foods
Promotes formation of the proteolytic enzyme, pepsin
Pepsin:- formed from pepsinogen when the pH of the
gastric content drops below 6 (pH<6)
Thus, the lack of gastric HCl could reasonably cause
gastrointestinal disturbances
5
8/30/2022 Mona. F(Medchem I)
5. 8/30/2022 6
Phases of Gastric Secretion
The gastric secretory process has been divided into three
phases:
Cephalic
Gastric &
Intestinal
With each phase leading to different amounts of acid
being secreted
Mona. F(Medchem I)
6. 7
Cephalic Phase
The sight, smell, taste, and sensation of
swallowing food causes central
stimulation of the vagus nerve leading to
ACh release from synapses within
the fundic and antral regions of the
stomach
Direct stimulation of the parietal cells
within the fundus and
To a lesser degree, the indirect
stimulation of Histamine release, through
vagally stimulated gastrin release from G-
cells within the antrum
Causes the parietal cells to secrete
acid into the stomach
8/30/2022 Mona. F(Medchem I)
7. Gastrin is the main mediator of acid secretion
Acid secretion occurs in response to both the presence of
nutrients and the physical distension produced by food entering
the stomach
Distension-induced gastric acid secretion, relative to the total
amount of acid released, is species dependent (human=20%;
dog=50%; rat = 38%)
The chemical constituents of a meal are the strongest stimulant
of gastrin release and acid output during the gastric phase
With peptides and amino acids being greater stimulants of
gastrin than proteins, carbohydrates, and fats
8
Gastric Phase
Mona. F(Medchem I)
8. Intestinal Phase
Only a relatively small amount of acid is secreted
Because of the numerous inhibitory mechanisms stimulated
by the presence of nutrients within the intestinal lumen
Acid is secreted by the parietal cells of the gastric mucosa
Parietal cells contain H+ ion pump
A unique H3O+/K+ ATPase system
That secretes H3O+ in exchange for the uptake of K+ ion
9
8/30/2022 Mona. F(Medchem I)
9. Introduction cont.
The secretion of gastric acid occurs at the level of parietal cells
of the oxyntic gland in the gastric mucosa
Producing 2-3 L of gastric juice per day
Ultimately, this secretory process occurs via H+/K+-ATPase
that exchanges hydronium ion with uptake of a potassium ion
Several mediators regulate this secretion by way of receptor
systems on the basolateral membrane
The H2 histaminergic pathway is cAMP dependent
Gastrin & muscarinic receptors also regulate the secretion of
gastric acid through calcium ion dependent pathways
10
8/30/2022 Mona. F(Medchem I)
10. Introduction cont.
In parietal cells, E-series prostaglandins work in opposition to
the histaminergic pathways
Inhibiting histamine-stimulated adenylyl cyclase activity
Other epithelial cells in the mucosal lining under the influence of
prostaglandin-mediated pathways secrete bicarbonate &
mucus
Both of which are important in protecting the gastric lining
from the effects of acid secretion
In many cases, hypersecretion of gastric acid appears to be
associated with H.pylori infection
Which may contribute to defects in mucosal protective
defenses
11
8/30/2022 Mona. F(Medchem I)
12. Inhibition of gastric acid secretion
Also occurs during the cephalic, gastric, and intestinal phases
In the cephalic phase, the release of various neuropeptides may contribute to
the inhibition of gastric acid secretion
Central injection of neuropeptide Y (NPY), corticotrophin-releasing
factor, bombesin, calcitonin, calcitonin gene-related peptide, neurotensin,
interleukin 1, and prostaglandins have all been shown to inhibit gastric
acid secretion
The hypothalamus appears to be an important site of action of many
peptide inhibitors of acid secretion
Of the peptides studied so far, only NPY exerts
Both stimulatory and inhibitory effects on acid secretion when
injected into different hypothalamic sites
13
8/30/2022 Mona. F(Medchem I)
13. Inhibition of gastric acid secretion cont.
In the gastric phase
Increasing gastric acidity initiates
A mechanism that turns off gastric acid secretion
Once the acidity of the lumen has reached pH 2
Gastrin release is inhibited and therefore acid
secretion is reduced
Stimulation of somatostatin release from D-cells in the
antrum of the stomach
Inhibits the release of gastrin from G-cells and thus
reduces gastric acid secretion
In patients with a duodenal ulcer, this inhibitory
process is less efficient, especially when
intraluminal pH falls below 3
14
8/30/2022 Mona. F(Medchem I)
14. Inhibition of gastric acid secretion cont.
In the intestinal phase
Inhibition of acid secretion is produced by the presence of
fat, acid, or hyperosmolar solutions within the intestinal
lumen
Fat, the most potent inhibitor, was proposed to cause the
release of inhibitory substances from the intestine although
no substances were formally identified, they were termed
enterogastrones
The release of cholecystokinin (CCK) and somatostatin,
in response to intestinal acid, inhibits gastric acid
secretion
15
8/30/2022 Mona. F(Medchem I)
15. Gastrointestinal Disorders
Gastritis
Irritation and superficial erosion of the stomach lining
Ulcerative colitis
Form of inflammatory bowel disease
Irritation and inflammation of the large bowel
Characterized by bloody mucus leading to watery diarrhea with blood,
mucus, and pus (A fluid product of inflammation)
Crohn’s disease
Inflammatory bowel disease
Can affect any portion of tubular GI tract
Malabsorption syndrome-Impaired intestinal absorption of nutrients
Cystic fibrosis: GI and pulmonary disease
GI tract: increased viscosity of mucus secretions and deficiency in pancreatic
enzymes
GI therapy consists of replacing pancreatic enzymes and vitamin
supplementation
Gastroesophageal reflux disease (GERD) 16
8/30/2022 Mona. F(Medchem I)
16. Gastrointestinal Agents
Agents used to treat gastrointestinal disturbance are known as
gastrointestinal agents
Agents used to treat gastrointestinal disorder include:
Products for altering gastric pH ,i.e. acidifying agents and
antacids
Protectives for intestinal inflammation
Adsorbents for intestinal toxins
Histamine H2-receptor antagonists
Proton pump inhibitors
Cathartic or laxatives for constipation
Antidiarrheal agents for diarrhea
Prostaglandins
Bismuth salt and antibiotic combinations
17
8/30/2022 Mona. F(Medchem I)
17. Acidifying agents
Achlorhydria
Is the absence of hydrochloric acid in the gastric secretion
Patients with this condition fall into two groups:
I) Those who remain free of gastric HCl after stimulation with histamine
phosphate
Caused by
Subtotal gastrectomy (Surgical removal of all or part of the
stomach)
Atrophic gastritis (chronic gastritis with atrophy of the mucous
membrane & glands)
Carcinoma of the stomach
II) Those in whom there is normally a lack of gastric HCl but who respond to
stimulation by histamine phosphate
These patients include those with
Chronic nephritis ( inflammation of the kidney)
Chronic alcoholism
Tuberculosis, hyperthyroidism, pellagra
Sprus (a periodic fatty, frothy diarrhea)
Parasitic infections
Common in normal individuals after age 50
18
8/30/2022 Mona. F(Medchem I)
18. Achlorhydria
Symptoms of Achlorhydria
Mild diarrhea or frequent bowel movement
Epigastric pain/ upper middle portion of the abdomen/
Sensitivity to spicy food
Drugs used for treatment of Achlorhydria
Diluted hydrochloric acid has been utilized
5 ml of HCl added to 200 ml of water for administration
In order to prevent (avoid) exposure of dental parts to HCl, the use of a
drinking straw laid well back is recommended
Give 15 meq HCl
Glutamic acid hydrochloride (Acidulin)- a capsule
Ineffective (concluded by National Research Council)
Expensive
Give 1.7 meq HCl
19
8/30/2022 Mona. F(Medchem I)
19. Gastric Acid cont.
The inhibition of gastric acid secretion is a key therapeutic
target for
Ulcer disease
Gastroesophageal reflux disease (GERD)-Pathologic gastric hypersecretory
conditions (Commonly called heartburn)
Zollinger-Ellison syndrome (Syndrome consisting of intractable
peptic ulceration with gastric hypersecretion and hyperacidity )
Gastritis
Currently, this is achieved either by
Blocking the acid-secretory effect of histamine (HA)
through the use of Histamine H2-receptor antagonists or
Irreversibly binding to the H+/K+-ATPase with proton-pump
inhibitors (PPIs)
To prevent the release of H+ ions from the parietal cell
20
8/30/2022 Mona. F(Medchem I)
20. Gastric Acid cont.
The discovery that ulcers are linked to Helicobacter
pylori (H. pylori) infection has led to a new
therapeutic approach
Eradication of the bacteria is the principal target
In addition to ulcer disease
H2-receptor antagonists and PPIs are still
effectively used for alleviating the symptoms of
Gastritis, Zollinger-Ellison syndrome &
Gastroesophageal reflux disease (GERD)
21
8/30/2022 Mona. F(Medchem I)
21. Peptic ulcer disease
Peptic ulcer disease
Consists of a group of upper GIT disorders that result from
erosive action of acid & pepsin
Local defect or excavation of the surface of an organ or tissue
Duodenal ulcer and gastric ulcer are the most common forms
It also occurs in the esophagus and small intestine
Factors involved in the pathogenesis include
Hypersecretion of acid & pepsin
GI infection by Helicobacter pylori, a Gram-negative spiral bacteria
Three common types of Ulcer disease
• Gastric
• Duodenal
• Stress
22
8/30/2022 Mona. F(Medchem I)
22. Peptic Ulcer cont.
Gastric Ulcers
– Local excavation in the gastric mucosa
– Have malignant potential
– Occur more in men than women
– Prevalent in smokers and populations in the Western Hemisphere
– H. pylori is a common contributing factor
Duodenal Ulcers
– Peptic lesion in the duodenum
– Occur more in hypersecretors
– More difficult to treat than gastric ulcers due to the difficulty in
getting the medication to the duodenum.
Stress Ulcers
– Occur in the clinical setting
– Caused by severe physiological stress from serious illness; many times
patients are in the ICU
– Patients in ICU usually receive prophylactic therapy of H2-antagonists
23
8/30/2022 Mona. F(Medchem I)
23. Peptic Ulcer cont.
H. pylori
Is the cause of most peptic ulcers
Secretes enzymes that neutralize stomach acid
Antibiotics are the mainstay of therapy
Mixed with an antacid or proton pump inhibitors
Goals of peptic ulcer disease therapy
To promote healing
Relieve pain
Prevent ulcer complications and recurrences
24
8/30/2022 Mona. F(Medchem I)
24. Drugs That May Cause Ulcers
Drug Adverse Effect
Alcohol Irritating to the GI tract
Aspirin Irritating to the GI tract
Anti-inflammatory drugs Reduce production of mucus
Corticosteroids Reduce the mucosal barrier
Potassium chloride Irritating to the GI tract
Methotrexate Irritating to the GI tract, ulceration,
hemorrhage
Iron Causes esophageal ulcers
25
8/30/2022 Mona. F(Medchem I)
25. Antacids
Most frequent therapy for gastric hyperacidity that involves the use of
basic inorganic antacids
Are drugs that react with HCl; hence neutralizes gastric HCl
pH rises and inhibits proteolytic activity of pepsin
They do not coat the mucosal lining, but may have a local astringent
effect
Astringents are drugs, which on local application precipitate the
surface proteins
Thus, protect the abraded mucus membrane & skin from
irritants & bacterial attack
Reduce inflammation of mucus membrane promote
healing, toughen the skin & decrease sweating
E.g. tannic acid, alum, aluminum acetate, aluminum chloride,
zinc oxide, calamine
26
8/30/2022 Mona. F(Medchem I)
26. Antacids cont.
An ideal antacid should be
Insoluble in water
In fine particle form
Rapid in onset & provide a
continuous buffering action
Longer duration of action
Not cause constipation
Not cause laxative effects
Not liberate CO2 & cause
rebound hyperacidity
Not produce systemic
alkalosis
Not interfere with
absorption of food
Not interfere with digestion
Palatable & inexpensive
Stable and readily available
27
8/30/2022 Mona. F(Medchem I)
27. Antacids cont.
Classification of antacids
There are differences in the types of antacids in terms of
their
Cationic content
Neutralizing capacity &
Duration of action
8/30/2022 28
Mona. F(Medchem I)
28. Antacids cont.
Antacids, which locally neutralize the hyperacidity, are
broadly grouped into two groups
Systemic (Absorbable) antacids
E.g. NaHCO3
Non-systemic (Non-absorbable) antacids
E.g. Aluminum salts, magnesium salts, CaCO3,
Sodium carboxymethyl cellulose
Those classified by their cationic metal includes
Sodium, Magnesium, Aluminum derivatives
29
8/30/2022 Mona. F(Medchem I)
29. Antacids cont.
Sodium antacids
Used in the treatment of metabolic acidosis
Should be avoided in hypertensive patients
NaHCO3 cause evolution of CO2
Belching (sudden escape of food or gas) &
flatulence (collection of gas in the stomach or bowel)
Magnesium antacids
Used for treatment of constipation
Cause diarrhea, decreased sense of taste
30
8/30/2022 Mona. F(Medchem I)
30. Aluminum antacids
Used to relieve acid indigestion and upset stomach
Cause constipation
Magnesium hydroxide and calcium carbonate have
a short, rapid effect.
Aluminum hydroxide has a slow, persistent effect
8/30/2022 31
Mona. F(Medchem I)
31. Combination antacid preparations
Antacids are used commonly in combination for three reasons:
To combine fast & slow reacting antacids in order to obtain a product
with a rapid onset & relatively sustained action
To lower a dose of each component & minimize the possibility of
certain adverse effects &
To use one component to antagonize one or more side effects of
another component
E.g. Laxative Vs constipation
E.g. aluminum hydroxide gel-magnesium hydroxide combination
alone or with Simethicone [Aludrox]
Simethicone
Not an antacid
Antiflatulant used in antacid combinations to defoam gastric
juice in order to decrease the incidence of gastroesophageal
reflux
32
8/30/2022 Mona. F(Medchem I)
32. H2-receptor antagonists
33
H2-receptor antagonists
Have an application in the treatment of acid-
peptic disorders such as
Peptic ulcer
Zollinger-Ellison syndrome (ulceration of duodenum)
Gastroesophageal reflux disease (GERD)
Acute stress ulcers
8/30/2022 Mona. F(Medchem I)
33. H2-Receptor Antagonists cont.
Histamine is a basic organic compound which has pKa
values of 9.4 (aliphatic primary amine) and 5.8
(imidazole)
Thus, it exists as an equilibrium mixture of tautomeric
cations at physiologic pH (7.4) with the
Monocation dominating (about 96%) over the dication
(about 3%) and the non-protonated species (about 1%)
34
8/30/2022 Mona. F(Medchem I)
34. H2-Receptor Antagonists cont.
H2-Receptor antagonist were result of modification of histamine
structure
It reversibly block action of histamine at H2 receptor and decreases
production of acid.
Attempts were made to develop specific histamine H2 receptor
antagonists based on the observation that
4-methyl histamine is a potent selective H2-receptor
agonist
N-guanyl histamine, a valuable lead compound was
subsequently discovered
Showed definite but weak H2 antagonism
Also showed a partial agonistic activity
35
8/30/2022 Mona. F(Medchem I)
35. H2-Receptor Antagonists cont.
Increasing length of the side chain of N-guanyl histamine
From two to four & coupled with replacement of the strongly
basic guanidino group by the neutral methyl thiourea
function gave
Burimamide, a specific H2 antagonist
With no detectable agonist activity & has low potency
and was poorly available orally but could not reach the
market
Modification of burimamide led to the discovery of other
drugs
36
8/30/2022 Mona. F(Medchem I)
36. H2-Receptor Antagonists cont.
Modification of the structure of burimamide gave metiamide
Has a methyl group at position 5 and isosteric replacement of one of the
carbons on the side chain of burimamide with sulfur
X-ray crystallography studies have indicated that
The longer thioester linkage in the chain increases the flexibility of
the side chain and
The 5- methyl substituent in the imidazole ring may help to
orientate the imidazole ring correctly for receptor binding
Metiamide is 10x more active than burimamide, and showed promise as
an anti-ulcer agent (full H2 antagonist)
Had higher potency and improved oral bioavailability
But toxic due to presence of thiourea
37
8/30/2022 Mona. F(Medchem I)
37. H2-Receptor Antagonists cont.
Replacement of thiourea sulfur of metiamide with a cyano-imino
function led to production of
Cimetidine (Tagamet®)
The name Tagamet (derived from anTAGonist and ciMETidine
Additional research gave related products such as
Ranitidine (Zantac®); Famotidine (Pepcid®), Nizatidine
(Axid®) were also produced with modification on the ring and
side chain
Ranitidine (Zantac)
– An aminoalkyl furan
– 4-10 times more potent than cimetidine
– Replacement of the furan ring by a thiazole group generates nizatidine
38
8/30/2022 Mona. F(Medchem I)
38. H2-Receptor Antagonists cont.
Nizatidine
– 5-18 time more potent than cimetidine
– Introduced into the UK in 1987 by the Lilly Corporation
– It is equipotent to ranitidine
– The furan ring in ranitidine is replaced with a thiazole ring
Famotidine (Pepcid)
– The basic dimethylaminomethyl group of nizatidine was replaced by the
guanidine functionality
39
8/30/2022
Famotidine
Mona. F(Medchem I)
39. SAR OF CIMETIDINE
• The finding that metiamide and cimetidine were both good H2-
antagonists of similar activity shows that the cyanoguanidine group
is a good bioisoster for the thiourea group
– Due to the possibility of three tautomeric forms for the guanidine group
compared to only one for the isothiourea group
• The imidazole ring can be replaced with other heterocyclic rings
such as a furan ring bearing a nitrogen containing substituent
– This led to the introduction of ranitidine
40
8/30/2022 Mona. F(Medchem I)
40. SAR of Ranitidine
The nitroketeneaminal group is optimum for activity
But may be replaced by other planar π systems capable of hydrogen bonding
Replacing the sulfur atom with a methylene group leads to a drop
in activity
Replacing the furan ring with more hydrophobic rings such as
phenyl or thiophene reduces activity
2,5-disubstitution is the best substitution pattern for the furan ring
Substitution on the dimethylamino group may be varied,
Showing that the basicity and hydrophobicity of this group are not crucial to
activity
Methyl substitution at carbon 3 or 4 of the furan ring
Eliminates activity, whereas the equivalent substitution on the imidazole
series increases activity
41
8/30/2022 Mona. F(Medchem I)
41. SAR of Famotidine
The sulfonylamidine binding group is not essential
May be replaced by a variety of structures as long as they are planar, have a dipole
moment, and are capable of interacting with the receptor by hydrogen
bonding
Activity is optimum for a chain length of 4 or 5 units
Replacement of sulfur with a CH2 group increases activity
Modification of the chain is possible with, for example, inclusion of an
aromatic ring
A methyl substituent on heterocyclic ring, ortho to the chain leads to a
drop in activity (unlike the cimetidine series)
3 of the 4 hydrogen's in the 2 guanidine NH2 groups are required for
activity
Famotidine
42
8/30/2022 Mona. F(Medchem I)
42. Proton pump inhibitors (PPIs)
Final step in gastric acid secretion is “proton pumping”, which is
mediated by an enzyme called H+/K+ ATPase
PPI blocks acid secretion by inhibiting the hydrogen-potassium
ion pump in parietal cells
Inhibition of the proton pump blocks basal and stimulated
secretion, i.e. Acid production due to
Histamine
Gastrin
Pentagastrin, a synthetic gastrin
Acetylcholine
43
8/30/2022 Mona. F(Medchem I)
43. Proton pump inhibitors (PPIs) cont.
The action of the H+/K+ ATPase pump (Proton pump)
Is the final step in the acid-secretion process of the parietal cell
B/C hydrogen ions are protons, this ion pump is also called the
proton pump
If the chemical energy is present to run the pump
It will transport the hydrogen ions out of the parietal cell
Which increases the acid content of the surrounding gastric
lumen and lowers the pH
The PPIs bind irreversibly to the proton pump
44
8/30/2022 Mona. F(Medchem I)
44. PPIs bind to the gastric proton pump (H+/K+-ATPase) on
the parietal cell membrane
Inactivating the exchange of H+ for K+ ions
This prevents the transport of HCl across the cell
membrane to the lumen of the stomach
Thus blocking the final step of acid production
PPI effectively stop over 90% of acid production in the stomach
For acid secretion to return to normal after the patient stops the PPI
The parietal cell must synthesize new H+/K+-ATPase
45
Proton pump inhibitors (PPIs) cont.
8/30/2022 Mona. F(Medchem I)
45. Proton pump inhibitors (PPIs) cont.
Discovery of proton pump inhibitors
Swedish medicinal chemists noticed that certain pyridylmethyl
benzimidazole sulfides were active PPIs
Conversion of these compounds to sulfoxide derivatives
Gave highly potent, irreversible inhibition of the Proton Pump
Substituted benzimidazoles are potent proton pump inhibitors
A good example is omeprazole (Prilosec®)
A prodrug that forms the active drug in the acidic biophase of parietal cells
o The active form irreversibly interacts with the target ATPase of the
pump
46
8/30/2022 Mona. F(Medchem I)
46. Proton pump inhibitors (PPIs) cont.
Mechanism of action of omeprazole
Omeprazole, in presence of an acid,
rearranges to a sulfenamide analogue
The sulfenamide analogue acts as
an irreversible inhibitor to the
ATPase
By forming a covalent disulfide
bond with a crucial sulfhydryl
group in the active site
The enantiomerically pure S-isomer
Esomeprazole has been marketed
separately as Nexium®
47
8/30/2022 Mona. F(Medchem I)
47. Figure: Acid-catalyzed activation of omeprazole to reactive sulfonamide. At the
parietal cell, H+/K+-ATPase, a cysteine residue, reacts to form disulfide-attached
enzyme inhibitor
48
8/30/2022 Mona. F(Medchem I)
48. Proton pump inhibitors (PPIs) cont.
The benzimidazole proton pump inhibitors
Possess efficiency in treating gastric ulcers and
With one or more antimicrobial activities can eradicate infection by H.
pylori
Currently four benzimidazole PPIs are approved for
marketing in the US
Omeprazole
Esomeprazole magnesium the enantiomerically pure S-
isomer
Lansoprazole
Pantoprazole sodium
Rabeprazole sodium
49
8/30/2022 Mona. F(Medchem I)
49. SAR of proton pump inhibitors
• Substituted benzimidazole, substituted pyridine and sulfinyl
chain connecting this two is essential for activity
• Benzimidazole substitution by electron withdrawing group will
increase activity.
• Benzimidazole substitution by electron donating group will
decrease activity
• 4 methoxy group on pyridine group increases biological activity
• 4 flouro alkoxy substitution results in strong inhibitory activity.
8/30/2022 50
Mona. F(Medchem I)
50. Cytoprotective agents and adsorbents
Commonly used for the treatment of mild diarrhea
Diarrhea is a frequent passage of fluid or semi-fluid
stool (more than 3 times daily)
Most products for the treatment of diarrhea will
consists of
A protective-adsorbent,
Antiviral & possibly antibacterial agents
Antidiarrheal agents should act directly on the smooth
muscles that
Decrease peristalysis & Increase segmentation
51
8/30/2022 Mona. F(Medchem I)
51. Cytoprotective agents and adsorbents cont.
They adsorb
Toxins,
Viruses and
Bacteria, along with providing protective coating of the intestinal
mucosa
They includes
Prostaglandins
Bismuth salts
Special clays
Activated charcoals
Carbenoxylone
Sucralfate
52
8/30/2022 Mona. F(Medchem I)
52. Cytoprotective agents and adsorbents cont.
Prostaglandins (PGs)
PG synthetase in the gut wall induce production of
prostaglandins
Are endogenous 20-carbon unsaturated fatty acids
Biosynthetically related to arachidonic acid
Have wide spread action on different parts of the body; such as
Cardiovascular System, Gastrointestinal smooth muscle,
Reproductive system, Nervous system, Platelets, Kidneys, eyes,
etc
53
8/30/2022 Mona. F(Medchem I)
53. Cytoprotective agents and adsorbents cont.
PGs of the E, F and I series are synthesized and
secreted in gastric juice
Thus, found in significant concentration in the GIT
Role of prostaglandins in GIT includes
Inhibition of basal and stimulated gastric acid and
pepsin secretion
Prevention of irritant induced gross mucosal lesions
of the stomach and intestine
Prostaglandins, in particular PGEs can inhibit histamine
stimulated HCl release with out interrupting mucosal flow
This makes them capable to protect the mucosa
A phenomenon termed cytoprotection
54
8/30/2022 Mona. F(Medchem I)
54. Cytoprotective agents and adsorbents cont.
Other effects of PGs include
Enhancement of mucosal blood flow
Stimulation of bicarbonate release
Increased mucus production
Because natural prostaglandins are not of pharmacological
selectivity and short-lived in vivo
Generally not possible to use them as cytoprotectants
55
8/30/2022 Mona. F(Medchem I)
55. Cytoprotective agents and adsorbents cont.
Prostaglandin E analogues
Are useful as cytoprotectants
A stable analogue for this purpose is misoprostol (Cytotec®)
Misoprostol has two structural features that makes it more stable
to metabolism than PGE1
The hydroxyl substituent is moved from 15 to 16 positions,
where it resides geminal to a methyl group
Greatly reducing metabolism by oxidation
Misoprostol is administered as the methyl ester
56
8/30/2022 Mona. F(Medchem I)
56. Cytoprotective agents and adsorbents cont.
The methyl ester is a prodrug form & must be cleaved prior
to activity
Misoprostol retains all cytoprotective attributes of PGE1
Other cytoprotectives related to misoprostol are
Enisoprost (Searle®)
Enprostil (syntex®)
57
8/30/2022 Mona. F(Medchem I)
57. Cathartics
Are intended to decrease absorption of substances by
Accelerating expulsion of the poison from the GIT
Are agents that increase fluidity of the intestinal
contents by
Retention of water, osmotic forces, indirectly
increase motor motility
Are employed to relieve constipation
Constipation-is an abnormally infrequent and
difficult passage of feces through the lower GI tract
that is characterized by difficult passage of hard &
dry stool
58
8/30/2022 Mona. F(Medchem I)
58. Cathartics
Also called Laxatives or Purgatives
Are drugs used to
Stimulate or increase the frequency of bowel evacuation or
Encourage the passage of a softer or bulkier stool
Generally classified in two groups
Osmotic cathartics
Increase fecal water content
Saccharide cathartics such as sorbitol
Sorbitol often combined with activated charcoal
To improve palatability of charcoal
To mask grittiness of the charcoal
59
8/30/2022 Mona. F(Medchem I)
59. Cathartics…
Saline cathartics
Increase osmotic pressure within the intestinal tract,
causing more water to enter the intestines
Magnesium sulfate; Magnesium citrate; Sodium sulfate
are some examples
Magnesium citrate Magnesium sulfate Sodium sulfate
8/30/2022 60
Mona. F(Medchem I)
60. Laxatives
Fall into several groups: Surfactants; Irritant laxatives; Bulk
laxatives
Surfactants
Act by detergent effect which enhances the mixing of fat &
water to soften stool
Prime example is dioctyl sodium sulfosuccinate
dioctyl sodium sulfosuccinate
61
8/30/2022 Mona. F(Medchem I)
61. Laxatives…
Irritant laxatives
Act by direct contact with the gastric mucosa
The resulting irritation causes a decrease in transit time
Examples are Danthron, Bisacodil, Phenolphthalein,
Castor oil and Senna
Danthron Bisacodil Phenolphthalein
8/30/2022 62
Mona. F(Medchem I)
63. Laxatives…
Bulk laxatives
Act by increasing stool volume
Examples are Psyllium based laxatives such as
Metamucil®; Methylcellulose containing
laxatives
8/30/2022 64
Mona. F(Medchem I)
64. Antiflatulant agents
Act by dispersing excess gas in the intestine before the
patient has the opportunity to do so
Examples are
Simethicone
A simple methylated siloxane Simethicone
Peppermint spirit
Activated charcoal
65
8/30/2022 Mona. F(Medchem I)
65. Emetics and antiemetics
Emetics
Used for induction of vomiting in patients who ingested
toxic materials
A few drugs are known
The morphine analogue – apomorphine
Can be used intravenously
Syrup of ipecac
A solution containing the emetic alkaloid emetine
Used orally to induce emesis
Both these drugs act by stimulating the stomach and a direct
effect on the chemoreceptor trigger zone (CTZ)
66
8/30/2022 Mona. F(Medchem I)
66. Nausea and Vomiting
The vomiting center in the
medulla receives impulses from
The chemoreceptor trigger zone (CTZ)
The CTZ receives input from
The cerebral cortex
The hypothalamus
Blood-borne stimuli
67
8/30/2022 Mona. F(Medchem I)
67. Antiemetics
Antiemetics
Are used in the treatment of nausea & vomiting
Variety of phenothiazine and related analogues used for this
purpose
Have a direct effect on the CTZ in the CNS
Prochlorperazine (Compazine®)[Phenothiazines]
Used as antiemetic
Not effective to prevent nausea due to motion sickness
Has minimal neuroleptic/Antipsychotic/effect
68
8/30/2022 Mona. F(Medchem I)
68. Antiemetics cont.
Compounds used for motion sickness include [Anticholinergic drugs]
Meclizine; Dimenhydrinate & Cyclizine are H1-R antagonist
Dimenhydrinate is a combination drug of diphenhydramine and 8-
Chlorotheophylline
Cyclizine Dimenhydrinate
69
8/30/2022 Mona. F(Medchem I)
69. Antiemetics cont.
Scopolamine (Muscarinic Receptor antagonist) patches are also effective
Are very useful in motion sickness, but are ineffective against
substances that act directly on the chemoreceptor trigger zone
Scopolamine
8/30/2022 70
Mona. F(Medchem I)
70. Antiemetics cont.
Ondansetron (Zofran®) and Granisetron (Kytril®)
Are selective 5-HT3 serotonin antagonists
Prevent nausea in patients receiving cancer chemotherapy
•
Ondansetron Granisetron
71
8/30/2022 Mona. F(Medchem I)
71. Antiemetics cont.
Corticosteroids: Dexamethasone and methylprednisolone
used alone are effective against mildly to moderately
emetogenic chemotherapy
Dexamethasone Methylprednisolone
8/30/2022 72
Mona. F(Medchem I)
72. Inflammatory Bowel Disease
Drugs used in the treatment of inflammatory bowel disease
Sulfasalazine (Azulfidine®)
A sulfonamide derivative used for prolonged treatment of ulcerative
colitis
Practically insoluble in water & Poorly absorbed from the intestine that
reaches the colon intact
In the colon bacterial azo-reductase enzymes cleave sulfasalazine
To sulfapyridine and 5-aminosalicylic acid (Mesalamine®)
5-aminosalicylic acid is the active product
Mechanism of action involves 5-aminosalicylic acid
• Inhibits synthesis of prostaglandin in the colon
• Thus, relieving the resultant inflammation
Metronidazole (Flagyl®)
An antibacterial agent, also used in the treatment of inflammatory bowel
Due to its bactericidal activity against H. pylori and other intestinal
bacteria
73
8/30/2022 Mona. F(Medchem I)
Dexamethasone is a fluorinated steroid that is 9-fluoropregna-1,4-diene substituted by hydroxy groups at positions 11, 17 and 21, a methyl group at position 16 and oxo groups at positions 3 and 20. It is a synthetic member of the class of glucocorticoids.
ethylprednisolone, or 6α-methylprednisolone, also known as 11β,17,21-trihydroxy-6α-methylpregna-1,4-diene-3,20-dione, is a synthetic pregnane steroid and a derivative of hydrocortisone (11β,17α,21-trihydroxypregn-4-ene-3,20-dione) and prednisolone (11β,17α,21-trihydroxypregn-1,4-diene-3,20-dione).